New RSV Antibody Treatment for Newborns Set to Launch in Sweden

Starting September 10, 2025, newborns in Sweden will have access to a new preventive antibody treatment against Respiratory Syncytial Virus (RSV). This initiative aims to provide protection to vulnerable infants ahead of the RSV season, which typically begins in the autumn. The antibody treatment will be administered either during a hospital visit post-birth or at a follow-up appointment.

The protective effects of the antibodies last for six months, as confirmed by Andreas Odlind, a senior physician. High-risk infants, particularly those with pre-existing health conditions, may be eligible for an additional dose prior to their second RSV season, as indicated by information from the health agency 1177.se.

Importantly, if mothers receive an RSV vaccination within two weeks of delivery, their newborns will not need this treatment. Historically, the cost of providing preventive measures to all newborns was prohibitive, but recent recommendations have shifted towards prioritizing infant health in this manner. RSV is recognized as a leading cause of respiratory complications in newborns and can result in severe respiratory issues, underscoring the importance of this new treatment initiative in safeguarding infant health in Sweden.